Overview: Histone Antibodies TestIntroduction: The Histone Antibodies Test detects histone antibodies to diagnose autoimmune diseases like lupus, causing joint pain or fatigue. Following 2023 ACR guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected systemic lupus erythematosus (SLE) or drug-induced lupus, ensuring targeted therapy.
Other Names: Histone Ab Assay, Lupus Autoantibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Histone antibody testing began in the 1980s with lupus research. Immunoassays improved in the 2000s, enhancing autoimmune diagnosis.
Purpose: Diagnoses autoimmune diseases like lupus, guides treatment, and monitors histone antibodies in patients with joint pain or fatigue.
Test Parameters: 1. Histone Antibodies
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like joint pain, fatigue, or rash, and list medications, especially those linked to drug-induced lupus (e.g., hydralazine).
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document joint pain, fatigue, rash, or history of autoimmune diseases. Include current medications, especially lupus-inducing drugs, and recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to detect histone antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for lupus evaluation.
Factors Affecting Result Accuracy: Improper sample handling or cross-reactivity with other autoantibodies can affect results. Drug-induced lupus may complicate interpretation.
Clinical Significance: Positive histone antibodies suggest SLE or drug-induced lupus, guiding immunosuppressive therapy. Negative results may require further autoantibody testing.
Specialist Consultation: Consult a rheumatologist for result interpretation and treatment planning.
Additional Supporting Tests: ANA, anti-dsDNA, or complement levels to confirm lupus or other autoimmune diseases.
Test Limitations: Non-specific for SLE; drug-induced lupus may yield similar results. Clinical correlation is needed.
References: ACR Lupus Guidelines, 2023; Arthritis & Rheumatology, Aringer M, 2022.
